2019
DOI: 10.4155/ppa-2019-0012
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of Cancer Metabolism: a Patent Landscape

Abstract: Cancer metabolism is currently a hot topic. Since it was first realized that cancer cells rely upon an altered metabolic program to sustain their rapid proliferation, the enzymes that support those metabolic changes have appeared to be good targets for pharmacological intervention. Here, we discuss efforts pertaining to targets in cancer metabolism, focusing upon the tricarboxylic acid cycle and the mechanisms which feed nutrients into it. We describe a broad landscape of small-molecule inhibitors, targeting a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 49 publications
0
1
0
Order By: Relevance
“…Although glycolysis inhibitors have not yet been approved in clinical practice, several glycolysis inhibitors have been developed and are currently being evaluated in preclinical and early clinical trials. 60,61 Given the negative effects of glycolysis on antitumor immunity, there is a clear rationale for combining checkpoint inhibitors with glycolysis inhibitors. Yet, there are concerns regarding the effect of glycolysis inhibitors on T cells, because T cells depend on glycolysis for their function.…”
Section: Combining Checkpoint Inhibitors With Glycolysis Inhibitorsmentioning
confidence: 99%
“…Although glycolysis inhibitors have not yet been approved in clinical practice, several glycolysis inhibitors have been developed and are currently being evaluated in preclinical and early clinical trials. 60,61 Given the negative effects of glycolysis on antitumor immunity, there is a clear rationale for combining checkpoint inhibitors with glycolysis inhibitors. Yet, there are concerns regarding the effect of glycolysis inhibitors on T cells, because T cells depend on glycolysis for their function.…”
Section: Combining Checkpoint Inhibitors With Glycolysis Inhibitorsmentioning
confidence: 99%